low impactOther MH Policyclinical_educationFederal

Substance Use Disorders Treatment Options

January 21, 2025Source: SAMHSA
20
Relevance score
Tangential

Impact on your practice

This is informational content about treatment options for substance use disorders. While useful for clinical knowledge, it has no direct impact on therapist billing, licensing, or practice requirements.

Key facts

1

Educational content on SUD treatment modalities and options

2

Part of SAMHSA's SUD Treatment Month awareness initiative

3

No policy or reimbursement changes

Therapy Companion analysis

This SAMHSA awareness initiative has minimal direct operational impact on your practice, but it signals important market and referral trends you should monitor. The document emphasizes that 48.5 million Americans (17% of the population) had a SUD in the past year, and that treatment combinations of behavioral therapy, medications, and recovery supports are evidence-based. If you're an LCSW, LPC, MFT, or psychologist, this means the demand for your services as part of integrated SUD treatment teams is substantial and growing. However, the document does not announce new reimbursement rates, prior authorization requirements, or billing code changes. Your income from SUD-related services will continue to depend on your existing insurance contracts and state Medicaid rates—this awareness campaign does not alter those. The emphasis on "combinations of behavioral therapies, medications, and recovery supports" suggests payers will increasingly expect you to document your role within a coordinated care model. If you're not currently tracking which of your clients have diagnosed SUDs or documenting your clinical coordination with prescribers and recovery programs, you should begin doing so to justify medical necessity and demonstrate value to insurers. The mention of FDA-approved medications (buprenorphine, methadone, naltrexone for opioids; acamprosate, disulfiram, naltrexone for alcohol) underscores that your therapeutic work is most billable when paired with pharmacotherapy—standalone counseling for SUD may face increasing scrutiny from payers seeking outcomes data.

Background

SAMHSA launched "SUD Treatment Month" in January 2025 as part of a broader federal effort to normalize and expand access to substance use disorder treatment. This reflects the ongoing opioid crisis and the Biden administration's focus on behavioral health integration. The document's emphasis on the DSM-5 diagnostic criteria and the distinction between SUD and addiction is meant to reduce stigma and encourage earlier intervention. Clinically, this is sound; operationally, it signals that federal agencies are pushing the narrative that SUD is a treatable medical condition requiring multidisciplinary care. For therapists, this creates both opportunity and pressure: opportunity because referrals and demand for your services should increase as awareness grows, but pressure because payers will expect you to demonstrate that your therapy is part of an evidence-based treatment plan that includes medication management and measurable outcomes.

What you should do

1

Audit your current SUD client population and documentation: identify which clients have a diagnosed SUD (using DSM-5 criteria), which are on FDA-approved medications, and whether you are documenting your clinical coordination with their prescriber. This data will help you justify medical necessity to insurers and prepare for payer audits.

2

Review your intake and assessment forms to ensure you are systematically screening for substance use using validated tools (SAMHSA's Screen4Success is mentioned as an example). If you are not screening, begin doing so to identify clients who may benefit from integrated treatment and to position your practice as part of the SUD treatment ecosystem.

3

Establish or strengthen referral relationships with prescribers, medication-assisted treatment (MAT) programs, and recovery support services in your area. Document these referrals in your clinical notes. Payers increasingly expect evidence of care coordination, and this documentation will support your billing and demonstrate value.

4

If you bill Medicaid, verify that your state's Medicaid program covers behavioral health services for SUD and confirm your reimbursement rate. Some states have enhanced rates for SUD treatment; others do not. This awareness campaign may prompt state legislatures to revisit SUD coverage, so monitor your state's Medicaid updates.

5

Prepare to articulate your specific role in SUD treatment (e.g., trauma-informed therapy, relapse prevention, family counseling) in your marketing and insurance credentialing materials. As demand grows, payers will want to understand what you offer and how it complements medication and peer support.

Notable excerpts

"Research shows that many people with SUDs respond well to combinations of behavioral therapies, medications, and recovery supports." (SAMHSA, January 2025) — This underscores that your therapy is most defensible to payers when documented as part of a coordinated, multimodal treatment plan.

"In 2023, 48.5 million people 12 or older, or 17 percent of the U.S. population, had a SUD within the past year." (SAMHSA, citing 2023 NSDUH) — This prevalence data supports the business case for expanding SUD services in your practice and justifies investment in staff training and referral partnerships.

"SUDs are often long-term health conditions that can carry risk of recurrence even after years of recovery." (SAMHSA, January 2025) — This language legitimizes ongoing therapeutic contact and supports billing for maintenance/relapse prevention services, not just acute treatment.

View full source text
Date: January 21, 2025 Categories: Treatment, Recovery, Substance Use Disorder (SUD) By: Avery Gollinge, M.S.W., C.P.S., Public Health Advisor and Helen Ploussiou, M.S.W., LCSW-C, B.C.D., Public Health Analyst, Center for Substance Abuse Treatment Many people make new promises to their health and well-being at the beginning of the year. To emphasize the value of expanding access to treatment for substance use disorders (SUDs), SAMHSA is launching “SUD Treatment Month” in January. This annual observance will be dedicated to spreading awareness about the effectiveness and availability of SUD treatment, giving people hope, and connecting individuals to treatment services and recovery supports that can improve their health and make their lives better. What Is Substance Use Disorder? SUDs are health conditions that typically develop over time in association with repeated substance use that changes the way the brain works. These changes can lead to compulsive cravings, reduced control over substance use, and continued use despite negative personal health and social consequences. SUDs range from mild to severe. Even when someone recognizes the harm caused by their substance use, they may struggle to manage or stop it. Not everyone who uses substances, though, develops a SUD. While every individual is different, SUDs often involve a complex interaction of genetics, biology, and environmental factors. For example, 50 percent of the risk of developing SUD is based on genetics, which can lead to SUDs occurring within families. Early childhood trauma also increases a person’s risk, as does starting to use substances before the age of 14 and/or having a mental health condition like depression or anxiety. Many people with SUD often find they have at least one of these risk factors. In 2023, 48.5 million people 12 or older, or 17 percent of the U.S. population, had a SUD within the past year, according to SAMHSA’s 2023 National Survey on Drug Use and Health (NSDUH). So, while not everyone with risk factors for a SUD develops one, SUDs are common. How Is SUD Different from Addiction? While the terms “substance use disorder” and “addiction” are often used interchangeably, they aren’t identical. Addiction refers to the most severe stages of a SUD. Not everyone with a SUD will experience addiction. That is especially true for alcohol use disorder, since most people with this condition have a mild severity. No matter the stage, people with a SUD can benefit from treatment and support, recognizing that SUDs are often long-term health conditions that can carry risk of recurrence even after years of recovery. How can a SUD be detected? Treatment and support start with recognizing that a person may have a SUD. Health professionals typically identify that a person might be at risk for a SUD by asking screening questions about someone’s use of substances. The diagnosis of a SUD is then made based on the person’s ability to control their use, and how it is impacting their health and well-being. The number of criteria, or symptoms, that a person has (as described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), Fifth Edition, from the American Psychiatric Association) determines the severity of their SUD. The DSM-5 recognizes SUDs associated with 10 different classes of drugs that include alcohol, caffeine, tobacco, and cannabis to opioids, stimulants, hallucinogens, inhalants, sedatives, and hypnotics. Individuals also may recognize that their relationship with substances is causing them problems, or their family members, friends, or co-workers may be worried about the impact substance use is having on a person. In these instances, screening tools such as SAMHSA’s Screen4Success may be helpful to gather information before seeking help from a healthcare professional or peer support. Treatments for SUD Once a SUD has been diagnosed, there are several treatment options to consider, including the setting in which to receive care. For example, some people will do well with treatment from their primary care provider while others may need more intensive treatment in a specialty SUD treatment facility. The specific combination of treatments and settings for care should be based on the individual's needs and may change over time as the person responds to treatment. Research shows that many people with SUDs respond well to combinations of behavioral therapies, medications, and recovery supports. Currently, the Food and Drug Administration (FDA) has approved medications to treat alcohol use disorder (AUD), opioid use disorder (OUD), and tobacco use disorder (TUD). FDA-approved medications for AUD (MAUD) include acamprosate, disulfiram, and naltrexone. Healthcare professionals may use other medications short-term to manage withdrawal from alcohol but acamprosate, disulfiram, and naltrexone are typically taken for longer periods of time and often in combination with counseling, other behavioral therapies, and recovery supports. Not everyone will respond the same way to each medication so it’s important to work with a healthcare provider to find the one that will work the best. Additional resources include Medication for the Treatment of Alcohol Use Disorder: A Brief Guide – 2015 and TIP 49: Incorporating Alcohol Pharmacotherapies Into Medical Practice. FDA-approved medications for the treatment of OUD (MOUD) include different formulations of buprenorphine, as well as methadone, and naltrexone. While they each work slightly differently, all three of these medications stabilize brain chemistry, block the euphoric (often referred to as the high) effects of opioids, relieve cravings, and normalize body functions without the negative and euphoric effects of opioids used. These medications can be used from months to a lifetime, safely. As with other medications, working with a healthcare practitioner to find the one that is right for a particular individual is important. Learn more about MOUD at Opioid Use Disorder: TIP 63: Medications for Opioid Use Disorder – 2021. Finding Treatment: Hope Is Closer Than You Think Even though SUDs are common and come with risks of recurrence, millions of people in the United States live healthy lives in recovery, managing their SUD health condition. Recovery from Substance Use and Mental Health Problems Among Adults in the United States (PDF | 439 KB) presents self-reports of recovery among adults 18 and older who thought they ever had a problem with their use of drugs or alcohol and/or mental health. These findings provide a clearer characterization of the factors associated with recovery among adults and how future efforts can foster a whole-health approach to sustain recovery from mental health and substance use conditions. If you or someone you care about is ready to take the first step towards treatment and recovery, there are resources to guide you. SAMHSA’s Behavioral Health Treatment Services Locator at FindTreatment.gov is a confidential, free tool that helps you search for treatment programs by location and type of service. It provides: - Residential and outpatient programs that offer specialty SUD treatment services. - Programs that provide MOUD and MAUD for opioid and alcohol use disorders. - Counseling and therapy services to address the consequences and contributing factors of SUDs. - Support groups and recovery programs to sustain recovery. - Advanced search filters under “show more” that factor in payment assistance and insurance, among other topics. For more information and resources on SUD Treatment Month, visit the SUD Treatment Month Toolkit. To learn how to get support for mental health, drug, or alcohol issues, visit FindSupport.gov. If you are ready to locate a treatment facility or provider, you can go directly to FindTreatment.gov or call 800-662-HELP (4357). If you or someone you know is struggling or in crisis, help is available. Call or text 988 or chat at 988lifeline.org. Treatment works. Recovery is possible.
Analysis by Therapy Companion AI policy engineConfidence: highAnalyzed: August 20, 2026

Policy changes drive denial patterns

Therapy Companion tracks both: the policy shifts on this page and the denial patterns hitting your claims.

Related policy changes

high75

[MA] H4895: Expanding access to mental health services

This bill aims to expand mental health service access in Massachusetts and has cleared committee with a favorable recommendation. Depending on final language, it could affect reimbursement rates, telehealth authorization, or insurance coverage requirements.

high72

[TN] SB1248: AN ACT to amend Tennessee Code Annotated, Title 4; Title 8; Title 33; Title 39; Title 49; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to mental health.

This comprehensive TN mental health bill touches multiple code sections and could affect licensure, scope of practice, insurance requirements, and workforce regulations. Therapists should monitor its progress closely as it moves through committee.

high70

Advancing the Future of Behavioral Health Data Exchange

This policy direction addresses a critical pain point for therapists: the lack of integrated health data exchange with primary care and medical providers. Improved interoperability could reduce documentation burden, improve care coordination, and reduce liability from medication interactions or missed diagnoses. However, it may also increase compliance requirements and data security obligations.

high68

Opinion: MAHA is rewriting the vocabulary of American mental health care

Federal deprescribing initiatives create new clinical and billing opportunities for therapists while potentially pressuring prescribing practices. Therapists should understand the evidence, reimbursement rules, and ethical considerations around medication tapering to protect clients and navigate changing clinical norms.